Huskisson E C, Wojtulewski J A, Berry H, Scott J, Hart F D, Balme H W
Br Med J. 1974 Feb 2;1(5900):176-80. doi: 10.1136/bmj.1.5900.176.
Fenoprofen, a compound with analgesic, anti-inflammatory, and antipyretic properties in animals, has been compared with placebo in a double-blind cross-over trial in 60 patients with rheumatoid arthritis. There was a statistically highly significant reduction in pain, duration of morning stiffness, analgesic requirements, and articular index, with increase in grip strength. There was no significant reduction in joint size or temperature. In a subsequent double-blind group-comparative study fenoprofen proved to be as effective as aspirin in relieving the symptoms of rheumatoid arthritis, with strikingly fewer side effects. Almost half of the patients taking aspirin were unable to tolerate the drug in adequate dosage for six months. The remainder were able to take on average only 4 g daily, and at this dose almost half still complained of tinnitus and deafness.Fenoprofen is likely to be useful for patients who cannot tolerate aspirin and other more toxic anti-inflammatory drugs or whose disease is not of sufficient severity to justify their use.
非诺洛芬是一种在动物体内具有镇痛、抗炎和解热特性的化合物，在一项针对60名类风湿性关节炎患者的双盲交叉试验中，已将其与安慰剂进行了比较。在疼痛、晨僵持续时间、镇痛需求和关节指数方面有统计学上非常显著的降低，握力增加。关节大小或温度没有显著降低。在随后的双盲组比较研究中，非诺洛芬在缓解类风湿性关节炎症状方面被证明与阿司匹林一样有效，且副作用明显更少。几乎一半服用阿司匹林的患者无法耐受足够剂量的药物达六个月之久。其余患者平均每天只能服用4克，在此剂量下，几乎一半的患者仍抱怨有耳鸣和耳聋症状。非诺洛芬可能对那些无法耐受阿司匹林和其他毒性更大的抗炎药物，或者其病情严重程度不足以证明使用这些药物合理性的患者有用。
